No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study by Hermsen, B.B.J. et al.
No efficacy of annual gynaecological screening in BRCA1/2
mutation carriers; an observational follow-up study
BBJ Hermsen1,11, RI Olivier2,11, RHM Verheijen1, M van Beurden2, JA de Hullu3, LF Massuger3, CW Burger4,
CT Brekelmans5, MJ Mourits6, GH de Bock7, KN Gaarenstroom8, HH van Boven9, TM Mooij10 and MA Rookus*,10
1Department of Obstetrics and Gynaecology, VU University Medical Centre, Amsterdam, The Netherlands; 2Department of Gynaecology,
The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands; 4Departments of Obstetrics and Gynaecology, Erasmus University Medical Centre, Rotterdam, The Netherlands;
5Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands; 6Department of Obstetrics and Gynaecology,
University Medical Centre Groningen, Groningen, The Netherlands; 7Department of Epidemiology, University Medical Centre Groningen, Groningen,
The Netherlands; 8Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands; 9Department of Pathology,
The Netherlands Cancer Institute, Amsterdam, The Netherlands; 10Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam,
The Netherlands
BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at
an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre,
observational, follow-up study we examined medical record data of a consecutive series of 888 BRCA1/2 mutation carriers who
started annual screening with transvaginal ultrasonography and serum CA125 between 1993 and 2005. The women were annually
screened for 75% of their total period of follow-up. Compliance decreased with longer follow-up. Five of the 10 incident cancers
were interval tumours, diagnosed in women with a normal screening result within 3–10 months before diagnosis. No difference in
stage distribution between incident screen-detected and interval tumours was found. Eight of the 10 incident cancers were stage III/IV
(80%). Cancers diagnosed in unscreened family members had a similar stage distribution (77% in stage III/IV). The observed number
of cases detected during screening was not significantly higher than expected (Standardized Incidence Ratio (SIR): 1.5, 95%
confidence interval: 0.7–2.8). For the subgroup that was fully compliant to annual screening, a similar SIR was found (1.6, 95%
confidence interval: 0.5–3.6). Despite annual gynaecological screening, a high proportion of ovarian cancers in BRCA1/2 carriers are
interval cancers and the large majority of all cancers are diagnosed in advanced stages. Therefore, it is unlikely that annual screening
will reduce mortality from ovarian cancer in BRCA1/2 mutation carriers.
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BRCA1/2 mutation carriers have a high lifetime risk of developing
ovarian cancer (39% for BRCA1, 11–22% for BRCA2 at age 70 years)
(Antoniou et al, 2003; Chen et al, 2006). To reduce the mortality of
ovarian cancer, BRCA1/2 mutation carriers are currently being
counselled for gynaecological screening and prophylactic bilateral
(salpingo-) oophorectomy (BP(S)O). Although efficacy of BPSO has
been demonstrated (Rebbeck et al, 2005), the efficacy of gynaecolo-
gical screening with (bi) annual transvaginal ultrasonography (TVU)
and the serum tumour marker CA125 (Karlan et al, 1993; Burke et al,
1997) is still unclear. To summarize the literature on gynaecological
screening of BRCA1/2 carriers, including overlap with the present
study, eight interval cancers among 24 cancers were diagnosed
among a total of 807 BRCA1/2 carriers (Table 1) (Laframboise et al,
2002; Liede et al, 2002; Scheuer et al, 2002; Fries et al, 2004; Kauff
et al, 2005; Meeuwissen et al, 2005; Vasen et al, 2005; Gaarenstroom
et al, 2006; Oei et al, 2006). Regretfully, most studies did not
distinguish between prevalent and incident cases. Also, compliance to
the intended screening protocol was generally unclear, whereas lack
of compliance may interfere with the efficacy of screening.
Especially for BRCA1/2 carriers, more information on compli-
ance and efficacy of gynaecological screening is urgently needed.
Although compliance to the protocol may be higher for BRCA1/2
carriers than for other high-risk women, efficacy of screening may
still be low. Ovarian tumours of carriers may have unfavourable
clinical–pathological characteristics and a higher growth rate
(Hogg and Friedlander, 2004). Moreover, carriers generally start
screening well before menopause, when temporary abnormalities
in TVU and CA125 for benign reasons are more common.
The purpose of this multicentre observational follow-up study
was to investigate the efficacy of annual gynaecological screening
taking compliance to the protocol into account. We compared
numbers and stages at diagnoses of incident interval cancers with
incident screen-detected cancers in a consecutive series of 888
BRCA1/2 carriers. In addition, we used two external comparisons:
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(1) ovarian cancers diagnosed in family members before
gynaecological screening was available and, (2) BRCA1/2 reference
curves for ovarian cancer.
MATERIALS AND METHODS
Study population
For this multicentre observational follow-up study, we identified a
consecutive series of all BRCA1/2 mutation carriers who started
gynaecological screening in six University Family Cancer Clinics in
the Netherlands (VU University Medical Centre, The Netherlands
Cancer Institute, Radboud University Nijmegen Medical Centre,
Erasmus University Medical Centre Rotterdam, University Medical
Centre Groningen, and Leiden University Medical Centre) in the
period 1993–2005. In total, 1035 women with a deleterious BRCA1
or BRCA2 mutation visited the gynaecologists. The specific
mutations were not known by the gynaecologists, but the
prevalence of BRCA1/2 mutations in the Netherlands have been
presented by Hout van der et al (2006). Women presenting with
complaints at first visit and women who visited the gynaecologist
only once were excluded. Among the remaining 888 women, five
prevalent cancers were detected at the first screening visit, leaving
883 women (683 BRCA1 and 200 BRCA2) for the evaluation of
screening during follow-up.
For analyses on compliance and sensitivity, we had to restrict
the study population to women who visited one of the three centres
(VU University Medical Centre, The Netherlands Cancer Institute
and Radboud University Nijmegen Medical Centre) where
information on each single screening visit (N¼ 601 of the total
group of 1035) was available, and to the 459 women who were
‘annually screened’, defined as having had at least one screening
visit with both screening tools and another visit to create time of
follow-up. Among the 459 women, two prevalent screen-detected
cases were detected, leaving 457 women for evaluation of annual
screening during follow-up.
Gynaecological screening
Since 1993, the national screening guideline implied annual visits
at the gynaecologist, including pelvic examination, TVU and
serum CA125 analysis (www.nvog.nl). From the late nineties
onward biannual visits have been introduced, though not system-
atically in all centres. For both BRCA1 and BRCA2 mutation
carriers, the minimum age of entry into the surveillance
programme was 35 years or 5 years earlier than the youngest age
at diagnosis of ovarian cancer in the family.
TVU findings were classified as abnormal for ovaries or
fallopian tubes, or normal including non-visualized ovaries. Serum
CA125 levels above 35 kU l1 were scored as abnormal if the
clinical decision based on these findings was an extra-screening
visit or a diagnostic operation (laparoscopy or laparotomy).
Prophylactic operation that followed a visit within 3 months, while
at this visit abnormalities were detected, was coded as diagnostic
operation (N¼ 8). Ovarian cancer cases were classified as
prevalent screen-detected cases (diagnosed at the first screening
visit), incident screen-detected cases (diagnosed at a regular
screening visit) or as incident interval cases (diagnosed as a result
of abdominal complaints, although no abnormalities were found at
the previous screening visit). All tumours were reviewed by one
pathologist (HvB).
Data collection
The data for this study comprised BRCA1/2 mutation status, first
and last gynaecological screening visits, prophylactic and diag-
nostic operation and pathology, as recorded in gynaecological
medical records and pathological reports. In three centres, detailedT
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data on each screening visit (date of visit, date of genetic testing,
TVU, CA125, and reason to stop screening) were collected. Part of
our pooled data was also used for earlier centre-specific
publications (Table 1).
We used two external control groups. First, in two centres
(Erasmus University Medical Centre Rotterdam and Netherlands
Cancer Institute) pedigree information and the hospital-based
cancer registry enabled us to trace anonymously tumours
diagnosed in family members of the screened BRCA1/2 carriers.
We evaluated those tumours diagnosed in the two centres before
gynaecological screening started (before 1990). Second, we used
BRCA1/2 reference curves of ovarian cancer derived as part of
refitting the BOADICEA model of genetic susceptibility to breast
cancer (Antoniou et al, 2002; Antoniou et al, 2004). Combined data
were used from three UK population-based studies of breast
cancer families (Peto et al, 1999; Angelian Breast Cancer Study
Group, 2000; Lalloo et al, 2003), with multiple cases of breast
cancer and family data from BRCA1/2 carriers identified in 22
population-based studies of breast and ovarian cancer (Antoniou
et al, 2003).
Statistical analysis
To calculate the Standardized Incidence Ratio (SIR), observed
numbers of ovarian cancer were compared with expected numbers,
based on the reference curves. Women were eligible for person-
years analysis if no ovarian cancer was detected at the first
screening visit. Starting date was defined as date of first visit,
stopping date as date of diagnosis of ovarian cancer (end point),
date of BP(S)O, or date of last screening visit, whichever was first.
In the three centres with information on each single screening
visit, the period of optimal annual screening was defined as the
period during which the national guideline (‘complete screening
visit’, i.e. visit with both TVU and CA125, every 13 months) was
met. Here, stopping date was defined as date of diagnosis of
ovarian cancer, date of BP(S)O, date of last complete screening
visit plus 13 months, or date of last visit, whichever was first.
Women who decide to be tested may be more likely to have
ovarian cancer than those who are not yet aware of their carrier
status and, thus, are not eligible for the study (Klaren et al, 2003).
If cancer events preceding the DNA test are included in the
analysis, overestimation of the incidence rate may occur. We
explored this potential testing bias by starting follow-up at date of
first complete screening visit or date of BRCA1/2 mutation testing,
whichever was later.
RESULTS
In total, 1035 BRCA1/2 carriers ever visited a gynaecologist for
screening advice and 883 BRCA1/2 carriers were actually screened
for 1473 women-years of follow-up. At first visit, the 683 BRCA1
carriers (77%, median age 40 years, range 21– 76 years) were on
average 3 years younger than the 200 BRCA2 carriers (23%,
median age 44 years, range 25–77 years, Figure 1).
Compliance and quality of screening tools
Among the 601 women with full data on each single visit, 118
women (19.6%) visited the Family Cancer Clinic only once
(Table 2), whereas 24 women with more visits were never screened
with both TVU and CA125. Most women opted out of screening for
valid reasons, like being too young (median age 28 years, range
20–34 years) or undergoing prophylactic operation (median
age 44 years, range 26 –75 years). Thus, the default rate was only
31/601¼ 5% in the total group, and 6% including the women with
missing data. Still, however, for 25% of the screening time (interval
between starting and stopping dates) the interval between two
complete screening visits was more than 13 months. This
proportion of non-compliance increased with longer follow-up.
The sensitivity of TVU and CA125 assessed simultaneously was
71%, and the positive predictive value 23% (Table 3). As shown in
Table 2, 311 of the 459 women (68%) opted for a BP(S)O and five
occult tumours were diagnosed. Including these tumours, the
sensitivity decreased to 42%.
Cases of ovarian cancer
At the first screening visit, five women (four BRCA1 and one
BRCA2) were diagnosed with a prevalent ovarian cancer (Table 4).
Among the remaining 883 BRCA1/2 carriers 10 women (all
BRCA1) were diagnosed with ovarian cancer during follow-up
(incident cases). Nine of the 10 incident cases had been compliant
to annual screening before diagnosis. In an efficiently screened
population, the majority of cancers would be detected by screening
instead of diagnosed following complaints. However, in our series
five of 10 incident cancers were unexpectedly diagnosed as a result
of abdominal complaints, although at the preceding visit no
abnormalities had been found. The five incident screen-detected
cases presented with both an abnormal TVU and CA125, although
no abnormalities were detected at the preceding visit (Table 4,
Figure 2). The family history of the 10 incident cases varied, three
cases had a breast-only family, one case an ovarian-only family
and six cases had both familial breast and familial ovarian cancer.
Seven cases (indicated in bold in Table 4) were diagnosed in the
group of 459 women that underwent annual screening in one of the
three centres with information on each screening visit. These 459
women came for 1116 screening visits during 690 annually
screened women-years (2.4 visits/woman and 1.6 visits/year)
(Figure 2). Abnormalities were detected in one or both of the
screening tools, at 38 out of 1116 regular screening visits (3%). For
24 women (5%), the abnormal findings were followed by 32 extra
visits at which 16 abnormalities persisted (50%). After normal
regular screening visits, complaints resulted in 26 visits for 21
women (5%) at which four abnormalities were found (15%). In
total, abnormalities were found in 40 women (9%) resulting in 26
diagnostic operations. No cancer was detected at nine operations
that followed abnormal TVU only, two cancers were detected at six
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Figure 1 Age distribution at first visit of 683 BRCA1 mutation carriers
compared with 200 BRCA2 mutation carriers.
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operations that followed abnormal CA125 only (33%), and five
cancers were detected at 11 operations (45%) that followed
abnormal findings in both screening tools. Compared to the next
to last visit, an exponential rather than progressive rise in serum
CA125 levels from the individual baseline level occurred at the last
visit for all incident screen-detected and interval cases (Figure 3).
Stages at diagnoses: interval vs screen-detected cancers
Advanced stages (III/IV) were diagnosed in all prevalent screen-
detected cases. For the incident screen-detected cases, the stages at
diagnosis were stage II (N¼ 1), stage III (N¼ 3) and stage IV
(N¼ 1), whereas for the incident interval cases, tumours were
diagnosed at stage II (N¼ 1), stage III (N¼ 2) and stage IV (N¼ 2).
At a mean follow-up since diagnosis of 28 months, three of the 15
cases listed in Table 4 died of ovarian cancer. The five occult
tumours detected at BP(S)O (Table 2) were diagnosed at stage I
(N¼ 4) and stage II (N¼ 1). Premalignant lesions in prophylacti-
cally removed tissue were not the scope of this study, but were
subject of separate hospital-based studies (e.g. Hermsen et al,
2006). In none of the women who were considered normal at
surgery, evidence of tumour growth occurred during follow-up, so
far.
Stages at diagnoses: comparison with cancers in
unscreened family members
If screening were effective, ovarian cancer would be diagnosed at
an earlier stage with better prognosis than would have been the
case without screening. We evaluated this potential shift in stage
by comparing the stages at diagnosis of the incident screen-
detected tumours with tumours diagnosed in family members
before gynaecological screening was available. In two centres, we
could trace 26 family members with ovarian cancer diagnosed
before 1990. Stages at diagnosis were stage I (N¼ 3), stage II
(N¼ 3), stage III (N¼ 19) and stage IV (N¼ 1). For the subgroup
of typed or obligate carriers (N¼ 16), the numbers were: stage I
(N¼ 2), stage II (N¼ 2), stage III (N¼ 12) and stage IV (N¼ 0).
Thus, the stage distributions of the screened and unscreened
groups were similar (stage III/IV: eight in 10 (80%) in the screened
group vs 20 in 26 (77%) in the unscreened group).
Comparison with external reference curves
If screening were effective, the diagnosis would shift to an earlier
age. We evaluated the lead-time by comparing the observed
number of cases with the number expected from age- and
mutation-specific external incidence curves, as estimated in an
international data set, comprising women that most likely were
less intensely screened (Antoniou et al, 2003). Given the rising
incidence curve at the young ages of the screened group, one
would expect the lead time to result in an increased SIR. However,
based on 10 incident cases observed and 6.5 cases expected, the
SIR was only 1.5 (95% confidence Interval (CI) 0.7– 2.8) (Table 5).
Among BRCA1 carriers, the SIR was 1.7 (95% CI: 0.8–3.1) and
among BRCA2 carriers the SIR could not be estimated with no
event observed and 0.5 expected. The SIR was 1.6 (95% CI 0.5–3.6)
if the analysis was restricted to the optimally screened women-
Table 2 Reasons not to start or to stop screening (at least annual screening with TVU and CA-125) for all 601 BRCA1/2 mutation carriers who visited the
gynaecologist at the Family Cancer Clinic in three centres
With follow-up Without follow-up
Total number
Screened with
both TVU and CA-125
Screened but never with
both TVU and CA-125
Status at end of follow-up N % N % N % N
In screening 97 21.1 4 16.6 9 7.6 110
Did not show up at appointment 14 3.1 4 16.6 13 11.0 31
Moved to other place/other gynaecologist 7 1.5 2 8.3 21 17.8 30
Too young 3 0.7 4 16.6 42 35.6 49
Too old 1 0.2 0 0 2 1.7 3
Prophylactic operationa 311 67.8 10 41.7 28 23.7 349
Missing 1 0.2 0 0 3 2.5 4
Diagnostic operation 25b 5.4 0 0 0 0 25
Total 459 100 24 100 118 100 601
aFive occult tumours were detected (4 stage I, 1 stage II). bOne woman had two diagnostic operations.
Table 3 Quality of screening tools used during combined multimodal gynaecological screening of 459 BRCA1/2 carriers during 1116 regular screening
visits
Test
Number of
casesa
Number of
unaffected women
Sensitivity (95%
CI)
Specificity
(95% CI)
Positive predictive
value (95% CI)
Negative predictive
value (95% CI)
CA-125, irrespective of TVU
+ 5 (5) 10 (10) 42% (14–70) 99% (99–100) 33% (9–57) 99% (99–100)
 7 (2) 1094 (1099) 71% (38–100) 99% (99–100) 33% (9–57) 100% (100–100)
TVU, irrespective of CA-125
+ 3 (3) 12 (12) 25% (1–50) 99% (98–100) 20% (0–40) 99% (99–100)
 9 (4) 1092 (1097) 43% (6–80) 99% (98–100) 20% (0–40) 100% (99–100)
CA-125 and/or TVU
+ 5 (5) 17 (17) 42% (14–70) 99% (98–99) 23% (5–40) 99% (99–100)
 7 (2) 1087 (1092) 71% (38–100) 99% (98–99) 23% (5–40) 100% (100–100)
CI, confidence interval. aIn italic: numbers and percentages without the five occult ovarian cancer cases, diagnosed during prophylactic operation, were included in the case group.
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years. As only one case was tested for BRCA1/2 mutation after the
diagnosis of ovarian cancer, testing bias did not markedly
confound the results (4% change of the SIR, data not shown).
DISCUSSION
We evaluated the actual gynaecological screening in a consecutive
series of 888 BRCA1/2 mutation carriers. Although compliance was
reasonably high (compliant for 75% of the follow-up), gynaeco-
logical screening did not seem to be effective, because (1) interval
tumours comprised five out of 10 incident cancers, (2) all women
diagnosed with an interval tumour had been compliant to annual
screening, (3) eight of the 10 cancers were diagnosed at stage
III/IV, (4) no difference in stage distribution between incident
screen-detected and interval tumours was found, (5) no difference
in stage distribution between incident screen-detected tumours
and tumours diagnosed in family members before 1990 was found,
and (6) in the total group as well as in the compliant group the
observed number of ovarian cancers was not markedly higher than
expected from reference curves, based on carriers of which the
majority was most likely not screened. Thus, although we could
not formally test efficacy with mortality as outcome, it is unlikely
that annual gynaecological screening will reduce mortality of
ovarian cancer in BRCA1/2 carriers.
Reported compliance of high-risk women to gynaecological
screening proved to vary extremely among studies (Lerman et al,
2000; Scheuer et al, 2002; Botkin et al, 2003; Vasen et al, 2005).
This may result from differences in definition of compliance,
differences in the requested frequency of screening visits and
differences in risk perception of the women and their physicians
(Tinley et al, 2004). For instance, in a series of 112 high-risk
women (29% BRCA1/2 carriers) adherence to annual TVUs was
only 19%, whereas in a group of 62 BRCA1/2 carriers adherence
was 68% to biannual screening with CA125 (Scheuer et al, 2002).
We found that women were compliant for 75% of their follow-up,
but valid reasons like pregnancies or breast cancer treatments may
partly explain why these BRCA1/2 carriers missed or delayed their
annual screening visits.
TVU and serum CA125 lack adequate sensitivity apart or
together (15–71% for TVU/CA125) (Laframboise et al, 2002;
Scheuer et al, 2002; Tailor et al, 2003; Meeuwissen et al, 2005;
Stirling et al, 2005; Olivier et al, 2006) and our finding of 42% for
TVU/CA125 is in accordance with these findings.
The external reference population that we used to calculate the
expected number of ovarian cancer, consisted of family members
of a largely population-based index case series, who were tested
positive in a research setting. Most of these women may not have
been aware of their carrier status and thus, might be less
intensively screened than the BRCA1/2 carriers in our study.
However, this assumption is not the only reason why the estimated
SIR should be interpreted with caution. Oral contraceptives
strongly protect against ovarian cancer (Antoniou et al, 2003;
Whittemore et al, 2004), and use of oral contraceptives might
Table 4 Cases diagnosed with ovarian cancers among 888 BRCA1/2 carriers during gynaecological screening
Second last screening
visit Last screening visita
DNA TVU
CA-125
(kU ml1)
Interval
between
visits
(months) TVU CA-125 (kU ml1) Detection
Age at
diagnosis
Histological
classification
(grade) FIGOStage Status
Follow-up
after diagnosis
(months)
1 BRCA2 NA NA NA Normal 331 Prevalent screen-
detected
77 Endometrioid (GIII) IIIB NED 31
2 BRCA1 NA NA NA Normal 113 Prevalent
screen-
detected
52 Serous (GIII) IIIC NED 5
3 BRCA1 NA NA NA Abnormal 188 Prevalent screen-
detected
56 Serous (GIII) IIIC SD 16
4 BRCA1 NA NA NA Normal 211 Prevalent screen-
detected
47 Serous (GII) IIIC NED 5
5 BRCA1 NA NA NA Normal 138 Prevalent
screen-
detected
45 Serous (GIII) IV RE 11
6 BRCA1 Normal 22 10 Abnormal 1693 Incident
interval
59 Endometrioid
(GIII)
IIC NED 3
7 BRCA1 Normal 15 4 Abnormal 15 Incident interval 73 Serous (GIII) IIIC NED 43
8 BRCA1 Normal 5 10 Abnormal 1450 Incident interval 38 Mucinous (GIII) IIIC SD 48
9 BRCA1 Normal 15 9 Abnormal 202 Incident interval 39 Serous (only
cytology)
IV SD 19
10 BRCA1 Normal 33 3 Abnormal 82 Incident
interval
33 Mucinous (GI) IV DOD 19
11 BRCA1 Normal 11 14 Abnormal 1815 Incident screen-
detected
43 Endometrioid (GII) IIC NED 34
12 BRCA1 Normal 12 13 Abnormal 159 Incident
screen-
detected
55 Serous (GIII) IIIB NED 28
13 BRCA1 Normal 10 11 Abnormal 105 Incident
screen-
detected
50 Endometrioid
(GIII)
IIIB DOD 39
14 BRCA1 Normal 11 6 Abnormal 48 Incident screen-
detected
73 Serous (GIII) IIIB DOD 41
15 BRCA1 Normal 24 12 Normal 217 Incident
screen-
detected
52 Serous (GIII) IV NED 75
DOD¼ death of disease; NA¼ not applicable; NED¼ no evidence of disease; RE¼ recurrence of disease; SD¼ stable disease. In bold: women diagnosed in one of the three
centres with information on each screening visit. aLast visit is last screenings visit for the interval and incident screen-detected cases.
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differ between our study sample and the reference population.
With these limitations in mind, the SIRs suggest that the lead-time
is very limited in the total and compliant group.
In evaluating efficacy of screening, several factors hamper the
comparison among various studies, (1) compliance to the intended
screening procedure has not been examined in combination with
efficacy, (2) generally, no distinction is made between prevalent
and incident screen-detected cases, (3) the screening protocol may
differ, such as the frequency of screening, the cutoff level of CA125
(15– 35 U ml1) (Bourne et al, 1994; Jacobs et al, 1999; Kauff et al,
2005; Meeuwissen et al, 2005; Olivier et al, 2006), and the
combined or sequential order of applying the screening tools
(Jacobs et al, 1999; Scheuer et al, 2002; Meeuwissen et al, 2005;
Stirling et al, 2005; Olivier et al, 2006), and (4) quality measures of
screening tools, like sensitivity, are typically reported including
occult tumours, while the proportion of women opting for a
BP(S)O differs strongly across various countries (Wainburg and
Husted, 2004). Consequently, the proportion of interval cancers
detected during screening varies among studies from 5/7¼ 71% in
the study by Liede et al (2002), 1/3¼ 33% in the study by Scheuer
et al (2002) and 1/6¼ 17% in the study by Vasen et al (2005)
(Table 1). In our study, the proportion of interval cancers was
5/15¼ 33% including the prevalent screen-detected cases and
5/10¼ 50% excluding the prevalent cases. Apart from this high
proportion of interval cancers, the unfavourable stages at
diagnoses for incident screen-detected cancers as well as for
interval cancers (stage III/IV: eight out of 10 cases in our study,
even excluding prevalent screen-detected cases) were quite
disappointing given the high compliance of cases. Moreover, the
stage distribution in our historical cases supported the lack of a
shift to lower stages by the introduction of screening. In other
studies, the stage distribution may be more (Scheuer et al, 2002) or
less (Liede et al, 2002) favourable, but power of most studies was
very low (Table 1).
In conclusion, annual gynaecological screening with TVU and
CA125 does not seem to be effective for BRCA1/2 carriers. In our
series, all but one case were diagnosed as a result of an abnormal
CA125 with or without an abnormal TVU. Thus, the question
remains, whether more frequent CA125 measurements would have
given better results. Seven of the 10 incident cases were diagnosed
9–14 months after the last visit with normal findings, suggesting
room for improvement. However, the three incident cases that
were diagnosed within 6 months of the last visit with normal
findings were all diagnosed at stage III/IV. Therefore, our limited
data on this issue do not suggest that the efficacy of gynaecological
screening will be significantly improved by more frequent screen-
ing with CA125, although evidence should come from trials.
Hopefully, the search for other tumour markers, for instance by
proteomics, will generate more promising alternatives. In a case–
control study, early stage ovarian cancer could be detected by
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Figure 3 CA125 levels of women with ovarian cancer detected at
regular screening visits (nos. 12, 13 and 15) or detected in between two
visits (i.e. interval ovarian cancer cases; 6 and 10); numbers of cases
consistent with Table 4.
3 incident
screendetected 
cases
None
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Figure 2 Flow diagram of the screening process. * Eight women had extra visits during follow-up. **One woman underwent diagnostic operation twice.
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taking three new biomarkers into account. The sensitivity of the
combination of apolipoprotein A1, transthyretin, H4 and CA125
was higher than CA125 alone (Zhang et al, 2004). A combination of
four other proteins was identified with microarray analysis (Mor
et al, 2005). However, clinical implementation of such early
findings will need confirmatory and prospective studies in larger
groups. In the general population, there are two major randomised
controlled trials being undertaken to assess the impact of
screening on ovarian cancer mortality; the UK Collaborative Trial
of Ovarian Cancer Screening (UKCTOCS) and the Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Trial in the
United States (Andriole et al, 2004; Menon, 2004, respectively).
For now, it is unlikely that annual gynaecological screening
with TVU and CA125 will reduce mortality from ovarian cancer
in BRCA1/2 mutation carriers. Prophylactic removal of the
ovaries and fallopian tubes has proven its value as a risk-reducing
strategy for ovarian cancer as well as breast cancer (Kauff
et al, 2002; Rebbeck et al, 2002; Finch et al, 2006) and should
therefore be the cornerstone in the management of BRCA1/2
mutation carriers, as long as no other effective screening tool is
available.
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